Data for: Endo-lysosomal assembly variations among Human Leukocyte Antigen class I (HLA-I) allotypes
Data files
Feb 19, 2023 version files 17.94 GB
-
Fig_1_-_6-30-22_moDC_bafilomycin_time_course.zip
59.53 MB
-
Fig_1_-_7-12-22_moDC_bafilomycin_time_course.zip
37.30 MB
-
Fig_1_-_7-15-22_moDC_bafilomycin_time_course.zip
228.44 MB
-
Fig_1_-_7-22-22_moDC_bafilomycin_time_course.zip
95.59 MB
-
Fig_1_-_7-25-22_moDC_bafilomycin_time_course.zip
63.32 MB
-
Fig_1_-_7-28-22_moDC_bafilomycin_time_course.zip
50.90 MB
-
Fig_1_-_7-7-22_moDC_bafilomycin_time_course.zip
193.36 MB
-
Fig_1_-_8-10-22_moDC_bafilomycin_time_course.zip
30.11 MB
-
Fig_1_-_8-18-22_moDC_bafilomycin_time_course.zip
13 MB
-
Fig_1_-_8-24-22_moDC_bafilomycin_time_course.zip
61.41 MB
-
Fig_1_-_8-29-22_moDC_bafilomycin_time_course.zip
45.36 MB
-
Fig_1_-_9-1-22_moDC_bafilomycin_time_course.zip
32.57 MB
-
Fig_1_-_9-3-22_moDC_bafilomycin_time_course.zip
8.19 MB
-
Fig_1_-_9-6-22_moDC_bafilomycin_time_course.zip
15.74 MB
-
Fig_1_2_4_-_1-14-22_moDC_baf_peptide_receptivity.zip
112.37 MB
-
Fig_1_2_4_-_1-21-22_moDC_baf_peptide_receptivity.zip
26.28 MB
-
Fig_1_2_4_-_3-24-21_moDC_peptide_receptivity.zip
79.63 MB
-
Fig_1_2_4_-_3-28-21_moDC_peptide_receptivity.zip
28.26 MB
-
Fig_1_2_4_-_4-11-21_moDC_peptide_receptivity.zip
85.18 MB
-
Fig_1_2_4_-_8-16-22_moDC_baf_peptide_receptivity_HC10.zip
83.86 MB
-
Fig_1_2_4_-_8-22-22_moDC_baf_peptide_receptivity_HC10.zip
19.12 MB
-
Fig_1_2_4_-_8-24-22_moDC_baf_peptide_receptivity_HC10.zip
15.73 MB
-
Fig_1_2_4_-_8-29-22_moDC_baf_peptide_receptivity_HC10.zip
26.37 MB
-
Fig_1_2_4_-_8-31-22_moDC_baf_peptide_receptivity_HC10.zip
14.63 MB
-
Fig_1_4_4S1_-_10-26-20_moDC_inhibitor_time_course.zip
38.19 MB
-
Fig_1_4_4S1_-_8-28-20_moDC_inhibitor_time_course.zip
30.42 MB
-
Fig_1_4_4S1_-_8-7-20_moDC_inhibitor_time_course.zip
31.43 MB
-
Fig_1_4_4S1_-_8-8-20_moDC_inhibitor_time_course.zip
20.60 MB
-
Fig_1_4_4S1_-_9-17-20_moDC_inhibitor_time_course.zip
45.31 MB
-
Fig_1_4_4S1_-_9-4-20_moDC_inhibitor_time_course.zip
53.68 MB
-
Fig_1_4S1_-_7-20-22_moDC_BBM1_peptide_receptivity.zip
26.07 MB
-
Fig_1_4S1_-_7-27-22_moDC_BBM1_peptide_receptivity.zip
43.99 MB
-
Fig_1_4S1_-_8-18-22_moDC_baf_peptide_receptivity_BBM1.zip
13.61 MB
-
Fig_1_4S1_-_8-22-22_moDC_baf_peptide_receptivity_BBM1.zip
16.75 MB
-
Fig_1_4S1_-_8-24-22_moDC_baf_peptide_receptivity_BBM1.zip
12.34 MB
-
Fig_1_4S1_-_8-29-22_moDC_baf_peptide_receptivity_BBM1.zip
32.04 MB
-
Fig_1_4S1_-_8-31-22_moDC_baf_peptide_receptivity_BBM1.zip
26.72 MB
-
Fig_1_4S1_-_9-1-22_moDC_baf_peptide_receptivity_BBM1.zip
6.51 MB
-
Fig_1S1_-_2-16-22_moDC_HLA-C_surface_total.zip
46.02 MB
-
Fig_1S1_-_3-15-22_moDC_HLA-C_surface_total.zip
92.02 MB
-
Fig_2_-_3-2-21_moDC_peptide_receptivity.zip
45.73 MB
-
Fig_2_-_4-26-21_moDC_peptide_receptivity.zip
87.36 MB
-
Fig_2_-_4-27-21_moDC_peptide_receptivity.zip
55.27 MB
-
Fig_2_-_5-17-21_moDC_peptide_receptivity.zip
31.51 MB
-
Fig_2_-_5-5-21_moDC_peptide_receptivity.zip
59.23 MB
-
Fig_2_-_6-13-21_moDC_peptide_receptivity.zip
70.67 MB
-
Fig_2_-_7-12-22_HLA-B_HC10_bead_pH_peptide_exchange.zip
43.98 MB
-
Fig_2_-_7-28-22_HLA-B_bead_pH_peptide_exchange.zip
46.18 MB
-
Fig_2_-_7-29-22_HLA-B_bead_pH_peptide_exchange.zip
48.12 MB
-
Fig_2_-_7-8-22_HLA-B_HC10_bead_pH_peptide_exchange.zip
44.77 MB
-
Fig_3_3S1_-_10-16-20_D148_monocyte_Bw6-EEA1.zip
161.76 MB
-
Fig_3_3S1_-_10-16-20_D187_monocyte_Bw6-EEA1.zip
153.46 MB
-
Fig_3_3S1_-_10-7-20_D166_moDC_Bw6-EEA1.zip
289.10 MB
-
Fig_3_3S1_-_10-7-20_D166_moDC_Bw6-LAMP1.zip
232.25 MB
-
Fig_3_3S1_-_10-7-20_D166_moDC_Bw6-Rab11.zip
255.80 MB
-
Fig_3_3S1_-_10-7-20_D187_moDC_Bw6-EEA1.zip
275.24 MB
-
Fig_3_3S1_-_10-7-20_D187_moDC_Bw6-LAMP1.zip
202.66 MB
-
Fig_3_3S1_-_10-7-20_D187_moDC_Bw6-Rab11.zip
204.31 MB
-
Fig_3_3S1_-_5-20-19_D187_monocyte_Bw6-LAMP1.zip
159.27 MB
-
Fig_3_3S1_-_5-20-19_D24_monocyte_Bw6-LAMP1.zip
209.21 MB
-
Fig_3_3S1_-_5-20-19_D55_monocyte_Bw6-LAMP1.zip
229.04 MB
-
Fig_3_3S1_-_6-17-19_D136_monocyte_Bw6-LAMP1.zip
230.08 MB
-
Fig_3_3S1_-_6-17-19_D178_monocyte_Bw6-LAMP1.zip
225.93 MB
-
Fig_3_3S1_-_6-27-19_D136_monocyte_Bw6-Rab11-Arf6.zip
397.74 MB
-
Fig_3_3S1_-_6-27-19_D178_monocyte_Bw6-Rab11-Arf6.zip
256.27 MB
-
Fig_3_3S1_-_7-24-19_D130_monocyte_Bw6-Arf6-Rab11.zip
189.25 MB
-
Fig_3_3S1_-_7-24-19_D130_monocyte_Bw6-EEA1-TAP1.zip
223.74 MB
-
Fig_3_3S1_-_7-24-19_D210_monocyte_Bw6-Arf6-Rab11.zip
262.81 MB
-
Fig_3_3S1_-_7-24-19_D210_monocyte_Bw6-EEA1-TAP1.zip
272.57 MB
-
Fig_3_3S1_-_8-11-20_D198_moDC_Bw6-EEA1.zip
253.50 MB
-
Fig_3_3S1_-_8-11-20_D198_moDC_Bw6-LAMP1.zip
319.27 MB
-
Fig_3_3S1_-_8-11-20_D198_moDC_Bw6-Rab11.zip
246.94 MB
-
Fig_3_3S1_-_8-11-20_D24_moDC_Bw6-EEA1.zip
265.91 MB
-
Fig_3_3S1_-_8-11-20_D24_moDC_Bw6-LAMP1.zip
216.12 MB
-
Fig_3_3S1_-_8-11-20_D24_moDC_Bw6-Rab11.zip
288.25 MB
-
Fig_3_3S1_-_8-11-20_D55_moDC_Bw6-EEA1.zip
181.89 MB
-
Fig_3_3S1_-_8-11-20_D55_moDC_Bw6-LAMP1.zip
252.78 MB
-
Fig_3_3S1_-_8-11-20_D55_moDC_Bw6-Rab11.zip
188.90 MB
-
Fig_3_3S1_4_4S1_-_1-20-21_D187_moDC_untreated_Bw6-LAMP1.zip
271.62 MB
-
Fig_3_3S1_4_4S1_-_3-22-21_D94_moDC_untreated_Bw6-LAMP1.zip
300.65 MB
-
Fig_3_3S1_4_4S1_-_3-26-21_D168_moDC_untreated_Bw6-LAMP1.zip
181.49 MB
-
Fig_3_3S1_4_4S1_-_3-26-21_D237_moDC_untreated_Bw6-LAMP1.zip
234.62 MB
-
Fig_3_3S1_4S1_-_1-20-21_D187_moDC_untreated_Bw6-Rab11.zip
473.74 MB
-
Fig_3_3S1_4S1_-_3-22-21_D94_moDC_untreated_Bw6-Rab11.zip
288.34 MB
-
Fig_3_3S1_4S1_-_3-26-21_D168_moDC_untreated_Bw6-Rab11.zip
222.34 MB
-
Fig_3_3S1_4S1_-_3-26-21_D237_moDC_untreated_Bw6-Rab11.zip
287.13 MB
-
Fig_4_-_6-20-19_PBMC_recycling_inhibitors.zip
41.37 MB
-
Fig_4_-_7-10-19_PBMC_recycling_inhibitors.zip
158.74 MB
-
Fig_4_-_7-9-19_PBMC_recycling_inhibitors.zip
144.37 MB
-
Fig_4_-_9-16-19_PBMC_recycling_inhibitors.zip
45.51 MB
-
Fig_4_-_9-26-19_PBMC_recycling_inhibitors.zip
46.10 MB
-
Fig_4_4S1_-_1-20-21_D187_moDC_bafilomycin_Bw6-LAMP1.zip
335.51 MB
-
Fig_4_4S1_-_3-22-21_D94_moDC_bafilomycin_Bw6-LAMP1.zip
267.59 MB
-
Fig_4_4S1_-_3-26-21_D168_moDC_bafilomycin_Bw6-LAMP1.zip
322.06 MB
-
Fig_4_4S1_-_3-26-21_D237_moDC_bafilomycin_Bw6-LAMP1.zip
385.40 MB
-
Fig_4_4S1_-_3-4-20_PBMC_MG132-Baf_treatment.zip
385.80 MB
-
Fig_4S1_-_1-20-21_D187_moDC_bafilomycin_Bw6-Rab11.zip
303.55 MB
-
Fig_4S1_-_1-23-20_PBMC_MG132_time_course.zip
32.68 MB
-
Fig_4S1_-_1-27-20_PBMC_MG132_time_course.zip
303.66 MB
-
Fig_4S1_-_2-5-20_PBMC_MG132_time_course.zip
330.48 MB
-
Fig_4S1_-_3-22-21_D94_moDC_bafilomycin_Bw6-Rab11.zip
287.33 MB
-
Fig_4S1_-_3-26-21_D168_moDC_bafilomycin_Bw6-Rab11.zip
336.49 MB
-
Fig_4S1_-_3-26-21_D237_moDC_bafilomycin_Bw6-Rab11.zip
370.10 MB
-
Fig_4S1_-_7-18-22_HLA-B_BBM1_bead_pH_peptide_exchange.zip
59.09 MB
-
Fig_4S1_-_7-23-22_HLA-B_BBM1_bead_pH_peptide_exchange.zip
62.63 MB
-
Fig_4S1_-_8-13-22_HLA-B_bead_pH_peptide_exchange.zip
23.51 MB
-
Fig_4S1_-_8-15-22_HLA-B_bead_pH_peptide_exchange.zip
21.98 MB
-
Fig_5_-_10-1-21_monocyte_DQ-Ova_time_course.zip
7.48 MB
-
Fig_5_-_10-20-21_monocyte_DQ-Ova_time_course.zip
12.81 MB
-
Fig_5_-_10-27-21_moDC_DQ-Ova_time_course.zip
50.77 MB
-
Fig_5_-_11-11-21_moDC_DQ-Ova_time_course.zip
53.54 MB
-
Fig_5_-_8-22-21_monocyte_DQ-Ova_time_course.zip
6.78 MB
-
Fig_5_-_8-27-21_monocyte_DQ-Ova_time_course.zip
68.52 MB
-
Fig_5_-_9-24-21_moDC_DQ-Ova_time_course.zip
96.51 MB
-
Fig_5A_-_3-31-21_moDC_antigen_uptake_rate.zip
20.27 MB
-
Fig_5A_-_4-2-21_moDC_antigen_uptake_rate.zip
6.93 MB
-
Fig_5A_-_4-2-21_monocyte_antigen_uptake_rate.zip
18.31 MB
-
Fig_5A_-_4-8-21_monocyte_antigen_uptake_rate.zip
66.16 MB
-
Fig_6_-_1-26-22_CTL_peptide_titration.zip
27.72 MB
-
Fig_6_-_1-28-22_CTL_peptide_titration.zip
39.75 MB
-
Fig_6_-_2-10-22_CTL_peptide_titration.zip
76.16 MB
-
Fig_6_-_2-11-22_CTL_peptide_titration.zip
57.81 MB
-
Fig_6_-_5_14_19_monocyte_cross-presentation_assay.zip
28.66 MB
-
Fig_6_-_5_3_19_monocyte_cross-presentation_assay.zip
6.68 MB
-
Fig_6_-_6_13_19_monocyte_cross-presentation_assay.zip
37.13 MB
-
Fig_6_7_-_1-13-21_monocyte_BZLF1_cross-presentation.zip
13.17 MB
-
Fig_6_7_-_1-20-21_moDC_BZLF1_cross-presentation.zip
17.38 MB
-
Fig_6_7_-_1-28-22_monocyte_EBNA3A_cross-presentation.zip
8.18 MB
-
Fig_6_7_-_1-6-21_moDC_BZLF1_cross-presentation.zip
31.39 MB
-
Fig_6_7_-_10-1-21_monocyte_CTI1_cross-presentation.zip
28.46 MB
-
Fig_6_7_-_10-13-21_moDC_CTI1_cross-presentation.zip
41.23 MB
-
Fig_6_7_-_10-26-21_monocyte_CTI1_cross-presentation.zip
5.17 MB
-
Fig_6_7_-_10-6-21_monocyte_CTI1_cross-presentation.zip
55.36 MB
-
Fig_6_7_-_10-8-21_moDC_CTI1_cross-presentation.zip
34.22 MB
-
Fig_6_7_-_10-8-21_monocyte_CTI1_cross-presentation.zip
13.23 MB
-
Fig_6_7_-_12-16-20_moDC_cross-presentation.zip
34.86 MB
-
Fig_6_7_-_2-14-22_monocyte_EBNA3A_cross-presentation.zip
30.39 MB
-
Fig_6_7_-_2-18-22_moDC_BZLF1_cross-presentation.zip
3.71 MB
-
Fig_6_7_-_2-21-20_monocyte_cross-presentation_assay.zip
11.57 MB
-
Fig_6_7_-_2-24-22_moDC_EBNA3A_cross-presentation.zip
11.12 MB
-
Fig_6_7_-_2-26-20_moDC_cross-presentation_experiment.zip
68.11 MB
-
Fig_6_7_-_2-4-22_moDC_EBNA3A_cross-presentation.zip
12.20 MB
-
Fig_6_7_-_3-12-20_moDC_cross-presentation_experiment.zip
51.59 MB
-
Fig_6_7_-_3-17-22_monocyte_EBNA3A_cross-presentation.zip
18.52 MB
-
Fig_6_7_-_3-22-22_monocyte_EBNA3A_cross-presentation.zip
27.94 MB
-
Fig_6_7_-_3-24-22_moDC_EBNA3A_cross-presentation.zip
43.03 MB
-
Fig_6_7_-_3-3-22_moDC_EBNA3A_cross-presentation.zip
56.59 MB
-
Fig_6_7_-_3-9-20_monocyte_cross-presentation_experiment.zip
15.01 MB
-
Fig_6_7_-_6-1-21_moDC_cross-presentation.zip
7.21 MB
-
Fig_6_7_-_8-25-22_monocyte_cross-presentation.zip
838.33 MB
-
Fig_6_7_-_8-29-20_moDC_cross-presentation_experiment.zip
37.31 MB
-
Fig_6_7_-_9-13-22_monocyte_cross-presentation.zip
33.51 MB
-
Fig_6_7_-_9-15-22_moDC_cross-presentation.zip
6.37 MB
-
Fig_6_7_-_9-15-22_monocyte_cross-presentation.zip
4.92 MB
-
Fig_6_7_-_9-16-20_monocyte_cross-presentation_experiment.zip
13.13 MB
-
Fig_6_7_-_9-7-22_moDC_cross-presentation.zip
13.58 MB
-
Fig_6_7_-_9-8-22_monocyte_cross-presentation.zip
6.81 MB
-
README.md
1.64 KB
Abstract
The extreme polymorphisms of HLA-I proteins enable the presentation of diverse peptides to cytotoxic T lymphocytes (CTL). The canonical endoplasmic reticulum (ER) HLA-I assembly pathway enables presentation of cytosolic peptides, but effective intracellular surveillance requires multi-compartmental antigen sampling. Endo-lysosomes are generally sites of HLA class II assembly, but human monocytes and monocyte-derived dendritic cells (moDCs) also contain significant reserves of endo-lysosomal HLA-I molecules. We hypothesized variable influences of HLA-I polymorphisms upon outcomes of endo-lysosomal trafficking, as the stabilities and peptide occupancies of cell surface HLA-I are variable. Consistent with this model, when the endo-lysosomal pH of moDCs is disrupted, HLA-B allotypes display varying propensities for reductions in surface expression, with HLA-B*08:01 or HLA-B*35:01 being among the most resistant or sensitive respectively, among eight tested HLA-B allotypes. Perturbations of moDC endo-lysosomal pH result in redistribution of HLA-B*35:01, but not HLA-B*08:01, to LAMP1+ compartments and increase HLA-B*35:01 peptide receptivity. These findings reveal the intersection of the vacuolar cross-presentation pathway with a constitutive assembly pathway for some HLA-B allotypes. Notably, cross-presentation of epitopes derived from two soluble antigens was also more efficient for B*35:01 compared to B*08:01, even when matched for T cell response sensitivity, and more affected by cathepsin inhibition. Thus, HLA-I polymorphisms dictate the degree of endo-lysosomal assembly, which can supplement ER assembly for constitutive HLA-I expression and increase the efficiency of cross-presentation.
Flow Cytometry, Microscopy and T cell assays.
Data can be accessed using FLow Jo and Image J.